Elan, Proteostasis Ink Research Agreement | June 6, 2011 Issue - Vol. 89 Issue 23 | Chemical & Engineering News
Volume 89 Issue 23 | p. 25 | Concentrates
Issue Date: June 6, 2011

Elan, Proteostasis Ink Research Agreement

Department: Business
Keywords: neurodegenerative disorders, dementia

Elan and Proteostasis Therapeutics are joining to advance Proteostasis’ technology for the discovery and development of small-molecule drugs and diagnostics that treat neurodegenerative disorders such as Parkinson’s disease and dementia-related diseases including Alzheimer’s. The partners will work on targets and compounds that modulate proteostasis network pathways. Elan will spend $20 million for a 24% stake in Proteostasis. It may provide up to $30 million more in funding and will have right of first negotiation for licensing compounds rising from the collaboration.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment